Stocks · News reference
TScan Therapeutics shares are trading lower after the company announced it paused further enrollment in the Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital needed to complete the trial. Also, the company will reduce its workforce by 75%.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Crude Oil Moves Higher; US Factory Orders Rise In July
U.S. stocks rose mid-session, led by materials; factory orders beat estimates. Linkhome, Purple Biotech and GitLab surged, while Tscan and Credo fell.
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction
The strategic pivot focuses TScan's efforts on developing in vivo-engineered TCR-T therapies.
Dow Surges Over 200 Points; Ollie's Bargain Outlet Shares Gain After Q2 Earnings
U.S. stocks edged higher, led by the Dow and materials. Ollie’s beat EPS estimates; biotech and AI shares surged, while Tscan plunged 26%.